BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8

Bulletin Express

Mar 03

BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.

The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1144819988"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144819988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144819988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144819988","market":"hk","top_or_hot":-1,"title":"BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8","media":"Bulletin Express","content":"<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioDlink International Company Limited (1875), Wuxi Biologics, and the Offeror Issue Clarification on Share Options Under Rule 3.8\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-03 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.</p>\n<p>The clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01875","symbol_name":"东曜药业-B","start_time":0,"source_url":"","article_id":"1144819988","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144819988","pubTimestamp":1772539511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01875":"东曜药业-B"},"translate_title":"BioDlink International Company Limited(1875)、药明生物及要约人根据第3.8条就购股权作出澄清","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1},"content_text":"BioDlink International Company Limited (1875), the Offeror, and Wuxi Biologics jointly referenced their previous announcements dated 14 January 2026, 12 February 2026, and 1 March 2026 regarding the Offers and related matters under the Takeovers Code. According to the announcement, after the vesting of 0.14 million Share Options on 1 March 2026, there are 7.63 million outstanding Share Options in total, comprising 7.49 million vested unexercised options and 0.14 million unvested options.\nThe clarification indicates that all other information and content presented in the 1 March 2026 announcement remain unchanged. The company reiterates that the clarification is supplemental and should be read alongside the previously issued announcement pursuant to Rule 3.8 of the Takeovers Code.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}